NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2009

Conditions

Macular Degeneration

Interventions

DRUG

JSM6427

Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.

Trial Locations (9)

29169

Palmetto Retina Center, West Columbia

40873

William Beaumont Research Institute, Royal Oak

57701

Black Hills Regional Eye Institute, Rapid City

73120

Dean McGee Eye Institute, Oklahoma City

77030

Vitreoretinal Consultants, Houston

78503

Valley Retina Institute, McAllen

79606

Retina Research Institute of Texas, Abilene

90211

Retina Vitreous Associates Medical Group, Beverly Hills

02114

Ophthalmic Consultants of Boston, Boston